

TO WHOM IT MAY CONCERN

RAMIPRIL CAPSULES – RELATED SUBSTANCES RAMIPRIL TABLETS – RELATED SUBSTANCES

An issue arising from the need to identify “*Impurity E*” has been brought to the attention of the British Pharmacopoeia Commission Secretariat.

This matter was discussed at the meeting of Expert Advisory Group MC2: Medicinal Chemicals on 1st May 2008, members agreed that further clarification is needed regarding the identity of impurity E (although impurity D and E are produced by two different synthetic routes). The British Pharmacopoeia Secretariat and Laboratory with the assistance of manufacturers are actively pursuing a means of positively identifying impurity E. It is hoped that a revised method will be published in the BP 2010.

If you have any questions concerning this letter please do not hesitate to contact the British Pharmacopoeia Secretariat at the address below.

Yours sincerely,



DR M G LEE

Secretary & Scientific Director

Tel: 020 7084 2561

E-mail: BPCOM@mhra.gsi.gov.uk

Letter of Intent reference: LOI/2008/004